Watson Center For Wellness Inc Social Worker - Clinical Medicare: Medicare Enrolled Practice Location: 103 S Main St, Canton, IL 61520 Phone: 309-649-6813 |
Lutheran Social Services Of Il Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 700 E Oak St, Suite 203, Canton, IL 61520 Phone: 309-647-3325 Fax: 309-647-0262 |
North Central Behavioral Health Systems, Inc. Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 229 Martin Ave, Canton, IL 61520 Phone: 815-223-0160 Fax: 815-223-1634 |
Jeanine Standard Metamorphosis Inc Psychologist - Clinical Medicare: Medicare Enrolled Practice Location: 8 S Main St, Suite 205, Canton, IL 61520 Phone: 309-740-2171 Fax: 309-740-2171 |
North Central Behavioral Health Systems, Inc. Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 229 Martin Ave, Canton, IL 61520 Phone: 815-223-0160 Fax: 815-223-1634 |
Tazwood Center For Wellness Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 210 W. Walnut Street, Canton, IL 61520 Phone: 309-647-5240 |
News Archive
Single-cell sequencing technologies are filling in fine details in the catalog of life. Researchers at the University of Connecticut Health Center and The Jackson Laboratory have identified 40 subtypes of retinal ganglion cells along with the genetic markers and transcription factors that differentiate them.
Amid some signs that America's obesity rates may be flattening out, media outlets report that one in three homeless people is obese and that bariatric surgery, which reduces stomach size, is becoming more common for patients as young as 12 or 13.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer's Japanese subsidiary, Bayer Yakuhin, Ltd., and Santen Pharmaceutical Co., Ltd. entered into a co-promotion agreement for EYLEA aflibercept) Injection in Japan.
In laboratory tests on multiple myeloma cells, University of Rochester researchers found that this type of cancer expresses a protein that makes it an easy target for an existing class of diabetes drugs. After more investigation, they hope the discovery will lead to a new, targeted therapy for myeloma patients.
Argos Therapeutics today announced that it has initiated dosing of patients in a Phase 2b clinical trial of its Arcelis™ personalized immunotherapy for the treatment of HIV patients, AGS-004.
› Verified 2 days ago